Budget impact analysis guidelines : guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada.: H82-49/2020E-PDF
"Budget impact analyses (BIAs) are used to predict and understand the potential financial impact of introducing a new pharmaceutical into a drug reimbursement system that has finite financial resources. While BIAs focus on the financial impact of the new drug, the value to the overall healthcare system is examined through other economic analyses, such as cost-effectiveness analyses (CEAs). In Canada, BIAs are used to make informed reimbursement decisions. These Guidelines provide a standardized approach and detailed recommendations for developing a BIA for submission to the Canadian Agency for Drugs and Technologies in Health (CADTH) or to one of the participating federal/provincial/territorial (FPT) drug plans"--Introduction, page 1.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.885893&sl=0
| Department/Agency |
|
|---|---|
| Title | Budget impact analysis guidelines : guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Earlier edition | Budget impact analysis guidelines : |
| Format | Digital text |
| Electronic document | |
| Note(s) |
|
| Publishing information |
|
| Description | 1 online resource (iv, 41 pages) |
| ISBN | 9780660345697 |
| Catalogue number |
|
| Edition |
|
| Subject terms |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.Page details
- Date modified: